Form 6-K NovaBridge Biosciences For: Aug 20
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 001-39173
NovaBridge Biosciences
2440 Research Boulevard, Suite 400
Rockville, MD 20850
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On August 20, 2026, NovaBridge Biosciences issued an investor presentation, a copy of which is furnished herewith as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NovaBridge Biosciences |
||
|
|
||
|
By |
: |
/s/ Kyler Lei |
|
Name |
: |
Kyler Lei |
|
Title |
: |
Chief Financial Officer |
Date: August 20, 2026
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pepe Coin Price Prediction Points to $0.000007 but Pepeto Offers a 100x Shot Before Listing Day
- The Boulder Group Releases Q3 2026 Net Lease Tenant Profiles Report
- Ascent Solar Technologies (NASDAQ: ASTI) Strengthens Defense & Space Strategy as NASA Results, Multi-Orbit Testing and Drone Demand Accelerate
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
